Cytodyn Inc
cytodyn.comWhat Do They Do?
Develops leronlimab, an antibody drug candidate being studied for solid-tumor cancers, including colorectal and triple-negative breast cancer.
10-K for FY2026, filed Aug 31, 2026The Company is a clinical-stage biotechnology company focused on the clinical development and potential commercialization of its product…View ↗
In August 2024, the Company completed a meeting with the FDA to gain alignment on the rationale and proposed dosing for a Phase 2 study…View ↗
Leronlimab and Metastatic Triple-Negative Breast Cancer (“mTNBC”)View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q1 FY2027, filed Oct 14, 2026
−$19.9MView ↗
- ▲ +260% (Loss)
- vs −$5.5M in Q1 FY2026
Narrower therapeutic focus
The older report described clinical development across HIV, NASH and solid-tumor oncology; the latest centers leronlimab development on solid-tumor oncology.
10-K for FY2023, filed Sep 14, 2023 10-K for FY2026, filed Aug 31, 2026CytoDyn’s core areas of clinical development are HIV, NASH, and solid tumors in oncology. The current areas of clinical focus in HIV are…View ↗
The Company is a clinical-stage biotechnology company focused on the clinical development and potential commercialization of its product…View ↗
Loading...
